
Verzenio + hormone therapy
Learn about the dosing and efficacy of Verzenio + hormone therapy and how they work inside the body.
What is Verzenio?
Verzenio in addition to your hormone therapy (tamoxifen or an aromatase inhibitor) can reduce your risk of recurrence vs hormone therapy alone.
Verzenio was studied in a clinical study of 5637 adults with HR+, HER2–, node-positive early breast cancer with a high chance of returning who had previously received primary treatment. In this study, 2808 patients were treated with Verzenio plus standard hormone therapy for 2 years, and then hormone therapy alone; 2829 patients received standard hormone therapy alone. The approval was based on a smaller group of 5120 patients from this study.
The recommended dose of Verzenio in combination with hormone therapy is 150 mg by mouth twice a day, taken once in the morning and once at night.
- Each pack contains your dose of 150-mg tablets for 7 days (14 individual 150-mg tablets)
- Multiple tablet strengths (50 mg, 100 mg, and 150 mg) allow your doctor to make dose adjustments based on how you tolerate the drug.
- No matter what dose is prescribed, you will take 1 tablet, 2 times a day, unless your doctor tells you otherwise.
Finally, treatment is moving forward, just like you. Verzenio is the first and only treatment in over 15 years to reduce the risk of recurrence in HR+, HER2– high-risk early breast cancer, when added to hormone therapy.
Results with Verzenio + hormone therapy
In a clinical study, Verzenio + hormone therapy was evaluated in people with HR+, HER2– early breast cancer with a high risk of recurrence based on extent of nodal involvement, tumor size, and tumor grade.
Protection against risk of recurrence
Verzenio helps kill cancer cells left behind after surgery, chemotherapy, and radiation to help prevent recurrence.
Verzenio + hormone therapy showed a 35% reduction in the risk of cancer returning compared with hormone therapy alone.
In a study, 85.5% of people taking Verzenio + hormone therapy were alive without their cancer returning vs 78.6% taking hormone therapy alone. Data was assessed at 48 months; the study is ongoing to see if there is a survival benefit.
Now there's an opportunity to reduce the risk of cancer returning with Verzenio when added to hormone therapy.
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. If you develop diarrhea during treatment, your healthcare provider may tell you to temporarily stop taking it, stop your treatment, or decrease your dose. If you have any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away.
What makes Verzenio different?
Verzenio has been used to treat over 15,000 patients in the U.S. with certain types of HR+, HER2– metastatic breast cancer, and is FDA approved to treat patients with HR+, HER2–, node-positive, early breast cancer with a high risk of coming back, in combination with hormone therapy.
Verzenio is a first-of-its-kind treatment approved to further reduce the risk of cancer recurrence when added to hormone therapy vs hormone therapy alone.
Verzenio is a tablet and not an infusion. This means you do not need to go to your doctor's office for this treatment. However, you may need to see your doctor for other treatments or tests. You can take Verzenio in your own home, which could give you more flexibility in your daily life.
How Verzenio works
Learn more about starting on Verzenio.
Moving Forward My Way
For women with HR+, HER2–, node-positive early breast cancer with a high risk of coming back, moving forward with additional support can give you the confidence to be there for who and what matters most. See the story behind Verzenio + hormone therapy.

00:00-0:08
[A woman walks in a stony, barren landscape. She comes to a mountain of rocks and begins climbing. Once she reaches the top, she sees something in the distance. It’s revealed to be her son looking at a telescope in a wooded area. He motions for her to join him, and we cut back to her smiling.]
VO Pam: Moving forward with node-positive breast cancer is overwhelming. But I never just found my way, I made it. And did all I could to prevent recurrence.
00:09-00:17
[The woman and her son walk together toward the telescope, then look up at the sky and smile.]
AVO: Verzenio reduces the risk of recurrence of HR+, HER2–, node-positive, early breast cancer with a high chance of returning as determined by your doctor, when added to hormone therapy.
Caption: Reduce your risk of recurrence
Caption: Verzenio + hormone therapy showed a 35% reduction in the risk of cancer returning compared with hormone therapy alone. In a study, 85.5% of people taking Verzenio + hormone therapy were alive without their cancer returning vs 78.6% taking hormone therapy alone. Data was assessed at 48 months; the study is ongoing to see if there is a survival benefit.
00:18-00:22
[It’s now a different day, and the woman and her son are in a craft room unfurling a canvas. They splatter the canvas with paint.]
AVO: Hormone therapy works outside the cell while Verzenio works inside to help stop the growth of cancer cells.
Caption: Works inside the cell to help stop growth
Caption: Hormone therapy reduces estrogen that feeds cancer cells. When Verzenio inhibits CDK4 & 6 in healthy cells, it can lead to side effects, some of which may be serious. Based on pre-clinical studies.
00:23-00:29
[The woman and her son work on a homemade sculpture of a planet.]
AVO: Diarrhea is common, may be severe, or cause dehydration or infection. At the first sign, call your doctor, start an anti-diarrheal, and drink fluids.
Caption: At the first sign of diarrhea, call your doctor, start an anti-diarrheal medication, and drink fluids.
00:30-00:48
[Teachers and children are preparing a school theater for a play. The woman walks through the door of the theater holding props, then helps the children and teacher set up the stage. They unfurl the canvas she and her son painted with stars. We jump forward in time and see parents sitting in the audience waiting for the play to begin. The curtain opens, showing the children ready to perform a space-themed play. The teacher places a space helmet on the woman’s son as part of his costume and directs him onstage.]
AVO: Before taking Verzenio, tell your doctor about any fever, chills, or other signs of infection. Verzenio may cause low white blood cell counts, which may cause serious infection that can lead to death. Life-threatening lung inflammation can occur. Tell your doctor about any new or worsening trouble breathing, cough, or chest pain. Serious liver problems can happen. Symptoms include fatigue, appetite loss, stomach pain, and bleeding or bruising. Blood clots that can lead to death have occurred.
Caption: Common side effects include nausea, infections, low blood cells and platelets, decreased appetite, headache, abdominal pain, tiredness (fatigue), vomiting, and hair thinning or loss.
00:49-00:55
[The woman watches happily from the audience. The son performs on stage, looks for his mother’s face in the crowd, and smiles.]
AVO: Tell your doctor if you have pain or swelling in your arms or legs, shortness of breath, chest pain, and rapid breathing or heart rate, or if you are nursing, pregnant, or plan to be.
Caption: Tell your doctor about all your medical conditions and medications you take and if you are nursing, pregnant, or plan to be pregnant.
00:56-00:57
[The woman smiles back proudly at her son and applauds.]
VO Pam: I’m making my own way forward.
Caption: Available by prescription only. 1-844-VERZENIO (1-844-837-9364)
00:58-01:00
[The Verzenio and Lilly logos appear.]
AVO: Ask your doctor about everyday Verzenio.
Caption: Everyday Verzenio® abemaciclib 50 | 100 | 150 mg tablets twice a day. verzenio.com. For pricing information, please visit lillypricinginfo.com/verzenio or call 1-844-VERZENIO (1-844-837-9364)
Caption: Verzenio® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. PP-AL-US-3703 03/2023 ©Lilly USA, LLC 2023. All rights reserved.